Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study

作者：Caifeng Li, Ke Zhao, Qian Ren, Lin Chen, Ying Zhang, Guolin Wang, Keliang Xie · 发表于：Frontiers in Immunology · 年份：2025 · DOI：10.3389/fimmu.2025.1537172 · 被引用次数：4 · 研究领域：Lipoproteins and Cardiovascular Health、Sepsis Diagnosis and Treatment、Cardiac, Anesthesia and Surgical Outcomes

Background: Despite early goal-directed therapy, sepsis mortality remains high. Statins exhibit pleiotropic effects, including anti-inflammatory and antimicrobial properties, which may be beneficial during sepsis. Objective: To determine whether statins could improve the clinical outcomes in patients with sepsis. Methods: We conducted a retrospective cohort study using data from the Medical Information Mart in Intensive Care-IV (MIMIC-IV) database. Adult patients with sepsis were included in the analysis. The exposure factor of this study was statin use during the Intensive Care Unit (ICU) stay. The primary outcome was 28-day all-cause mortality. The secondary outcomes were ICU and in-hospital mortality, length of ICU stay and hospital stay, duration of mechanical ventilation (MV) and continuous renal replacement therapy (CRRT). Both propensity score matching (PSM) and stepwise regression analyses were employed to adjust for potential confounders. Results: The unmatched cohort comprised 20230 eligible patients, with 8972 patients in the statin group and 11258 in the no statin group. Propensity score matching generated balanced cohorts with 6070 patients in each group. Post-PSM analysis revealed significantly lower 28-day all-cause mortality in the statin group (14.3% [870/6070]) compared to the no statin group (23.4% [1421/6070]). Statin use was associated with decreased 28-day all-cause mortality (hazard ratio [HR], 0.56; 95% confidence interval [CI], 0.52-0.61; p < 0.001). ...